Hormone therapy is medically necessary for many transgender individuals. The U.S. Food and Drug Administration (FDA) and pharmaceutical companies' failure to guarantee a supply of injectable estrogen in 2016 and 2017 for transgender individuals is a violation of their right to comprehensive medical treatment, free of discrimination. A series of advocacy actions eventually led to all formulations of injectable estrogen being restored to market; however, long-term solutions to supply interruptions of injectable estrogen are needed. Long-term solutions should address the lack of federally funded research and, consequently, evidence-based practice on hormone therapy for gender affirmation.
Get full access to this article
View all access options for this article.
References
1.
FeldmanJ, SpencerK. Chapter 18 Medical and surgical management of the transgender patient: what the primary care clinician needs to know. In: Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health, 2nd Edition. (MakadonHJ, MayerKH, PotterJ, GoldhammerH; eds). Philadelphia: American College of Physicians, 2015, pp. 479–511.
2.
GlynnTR, GamarelKE, KahlerCW, et al.The role of gender affirmation in psychological well-being among transgender women. Am Psychol Assoc. 2016; 3:336–344.
3.
Gómez-GilE, Zubiaurre-ElorzaL, EstevaI, et al.Hormone-treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology. 2012; 37:662–670.
4.
DeutschMB. Overview of feminizing hormone therapy. Center of Excellence for Transgender Health. 2016. Available at: http://transhealth.ucsf.edu/trans?page=guidelines-feminizing-therapy Accessed October6, 2017.
5.
Fenway Health. The medical care of transgender persons. Fenway Health. 2015. Available at: www.lgbthealtheducation.org/wp-content/uploads/COM-2245-The-Medical-Care-of-Transgender-Persons.pdf Accessed October6, 2017.
6.
U.S. Food & Drug Administration. Current and resolved drug shortages and discontinuations reported to FDA: estradiol valerate injection. FDA. 2017. Available at: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Estradiol%20Valerate%20Injection,%20USP&st=r&tab=tabs-1 Accessed October6, 2017.
7.
U.S. Food & Drug Administration. Current and resolved drug shortages and discontinuations reported to FDA: estradiol valerate injection. FDA. 2016. Available at: www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Estradiol%20Valerate%20Injection,%20USP&st=c Accessed October6, 2017.
8.
MooreC. Exclusive: there's an injectable estrogen shortage that's leaving trans women in Crisis. Out. 2016. Available at: www.out.com/out-exclusives/2016/8/04/exclusive-theres-injectable-estrogen-shortage-thats-leaving-trans-women Accessed October6, 2017.
9.
GeffenS, HornT, SmithKJ. Resolving the current injectable estrogen shortage: a public health imperative. The Fenway Institute, Treatment Action Group, and Callen-Lorde Community Health Center. 2016. Available at: fenwayhealth.org/wp-content/uploads/Resolving-the-current-injectable-estrogen-shortage-A-public-health-imperative.pdf Accessed October6, 2017.
10.
HRC Staff. HRC Takes Action on Injectable Estrogen Shortage. Human Rights Campaign. 2016. Available at: https://www.hrc.org/blog/hrc-takes-action-on-injectable-estrogen-shortage Accessed October6, 2017.
11.
Lambda Legal. Professional organization statements supporting transgender people in health care. Lambda Legal. 2013. Available at: https://www.lambdalegal.org/publications/fs_professional-org-statements-supporting-trans-health Accessed March5, 2018.
12.
SpackNP. Management of transgenderism. JAMA. 2013; 309:478–484.
13.
KreukelsBP, Cohen-KettenisPT. Puberty suppression in gender identity disorder: the Amsterdam experience. Nat Rev Endocrinol. 2011; 7:466–472.
14.
MuradMH, ElaminMB, GarciaMZ, et al.Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf). 2010; 72:214–231.
15.
OlsonJ, ForbesC, BelzerM. Management of the transgender adolescent. Arch Pediatr Adolesc Med. 2011; 165:171–176.
16.
Fenway Health. The medical care of transgender persons. 2015. Available at: www.lgbthealtheducation.org/wp-content/uploads/COM-2245-The-Medical-Care-of-Transgender-Persons.pdf Accessed October6, 2017.
17.
The U.S. Food and Drug Administration. Estrogen and estrogen with progestin therapies for postmenopausal women. FDA. 2016. Available at: www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm Accessed October6, 2017.
